Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 μg | In stock | $ 386.00 | |
200 μg | 5 days | $ 682.00 | |
500 μg | 5 days | $ 1,440.00 |
Biological Information |
1. Measured by its binding ability in a functional ELISA.
2. Immobilized mouse VEGFR3-His at 10 μg/mL (100 μl/well) can bind mouse Fc-VEGFD, The EC50 of mouse Fc-VEGFD is 44 ng/mL.
|
Description | Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Species | Mouse |
Expression System | HEK293 |
Tag | His |
Accession Number | P35917-1 |
Synonyms | Flt-4, VEGFR-3, Chy, fms related tyrosine kinase 4, VEGFR3, AI323512 |
Construction | A DNA sequence encoding the mouse FLT4 (P35917-1) extracellular domain (Met 1-Glu 775) was expressed, with a polyhistidine tag at the C-terminus. |
Protein Purity |
≥ 97 % as determined by SDS-PAGE ≥ 90 % as determined by SEC-HPLC.
|
Molecular Weight | Approxiamtely 86.4 kDa |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
Formulation | Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA. |
Reconstitution | A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information. |
Stability & Storage |
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Shipping |
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. |
Research Background | Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
VEGFR3/FLT4 Protein, Mouse, Recombinant (His) Flt-4 VEGFR 3 VEGFR-3 AI-323512 AI 323512 Chy fms related tyrosine kinase 4 VEGFR3 AI323512 recombinant recombinant-proteins proteins protein